Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 26 years of covering Asia Pacific equities, the past 20 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

3SBio (1530 HK)'s Spin-Off and Listing of Mandi Inc.

Quiddity Advisors

Event-Driven

<ul>
<li>Back on the 20th November 2025, pharma-play <strong><a href="https://www.smartkarma.com/entities/3sbio-inc" target="_blank" data-smartkarma-citation="entities:459:1" rel="noopener">3SBio (1530 HK)</a></strong> announced the spin-off and listing of 87.16%-held Mandi, a "<em>hair loss and weight management treatments</em>" solutions provider, on the HKEx. </li>
<li>3SBio will distribute its stake in-specie, together with a concurrent global offering. An EGM has been set for the 23rd April for shareholders to vote on the in-specie distribution.</li>
<li>Mandi accounted for 17% of 3SBio's revs in the 1H25, and 12.5% of profit. No updated figures for 2H25 have been provided. 3SBio's overall FY25 numbers were stellar. </li>
</ul>


Back on the 20th November 2025, pharma-play 3SBio (1530 HK) announced the spin-off and listing of 87.16%-held Mandi, a "hair loss and weight management treatments" solutions provider, on the HKEx. 
3SBio will distribute its stake in-specie, together with a concurrent global offering. An EGM has been set for the 23rd April for shareholders to vote on the in-specie distribution.
Mandi accounted for 17% of 3SBio's revs in the 1H25, and 12.5% of profit. No updated figures for 2H25 have been provided. 3SBio's overall FY25 numbers were stellar. 


Update On 3SBio (1530 HK)'s Spin-Off and Listing of Mandi